Replimune Group (REPL) Expected to Post Quarterly Earnings on Thursday

Replimune Group (NASDAQ:REPL) is expected to be posting its Q1 2027 results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.6097) per share and revenue of $13.6010 million for the quarter. Parties can check the company’s upcoming Q1 2027 earning report for the latest details on the call scheduled for Thursday, August 6, 2026 at 7:00 AM ET.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings data on Monday, June 29th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($0.10). On average, analysts expect Replimune Group to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Replimune Group Stock Up 1.1%

Shares of REPL opened at $5.41 on Thursday. The business’s fifty day moving average price is $9.35 and its two-hundred day moving average price is $7.37. The firm has a market capitalization of $454.12 million, a price-to-earnings ratio of -1.60 and a beta of 0.86. Replimune Group has a 52 week low of $1.50 and a 52 week high of $12.50. The company has a debt-to-equity ratio of 0.63, a quick ratio of 4.79 and a current ratio of 4.79.

Insider Activity at Replimune Group

In other Replimune Group news, insider Christopher Sarchi sold 12,000 shares of the company’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $9.24, for a total transaction of $110,880.00. Following the completion of the sale, the insider owned 180,962 shares in the company, valued at approximately $1,672,088.88. The trade was a 6.22% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 5.20% of the company’s stock.

Institutional Investors Weigh In On Replimune Group

A number of institutional investors have recently made changes to their positions in REPL. Inceptionr LLC acquired a new position in Replimune Group in the fourth quarter valued at about $172,000. JPMorgan Chase & Co. grew its position in shares of Replimune Group by 4.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 38,016 shares of the company’s stock worth $159,000 after buying an additional 1,712 shares during the period. Commonwealth Equity Services LLC acquired a new position in shares of Replimune Group during the 4th quarter worth about $150,000. Quadrature Capital Ltd bought a new stake in shares of Replimune Group in the 4th quarter valued at about $143,000. Finally, Oxford Asset Management LLP bought a new stake in shares of Replimune Group in the 2nd quarter valued at about $125,000. 92.53% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

REPL has been the topic of several research reports. Leerink Partners reaffirmed a “market perform” rating and set a $2.00 price target (down from $11.00) on shares of Replimune Group in a research note on Monday, April 13th. Jefferies Financial Group reiterated a “hold” rating and issued a $2.00 price objective (down from $13.00) on shares of Replimune Group in a research report on Monday, April 13th. BMO Capital Markets raised Replimune Group from an “underperform” rating to an “outperform” rating and set a $16.00 price objective for the company in a report on Tuesday, June 30th. HC Wainwright restated a “sell” rating on shares of Replimune Group in a research report on Monday, April 13th. Finally, Wedbush raised their target price on shares of Replimune Group from $6.00 to $9.00 and gave the company a “neutral” rating in a research note on Tuesday, June 30th. Two analysts have rated the stock with a Buy rating, five have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, Replimune Group presently has a consensus rating of “Hold” and a consensus price target of $8.86.

Key Replimune Group News

Here are the key news stories impacting Replimune Group this week:

• Neutral Sentiment: Trading activity has been unusually heavy, suggesting investors are repositioning ahead of the FDA’s upcoming advisory committee meeting. The current move appears more consistent with volatility and a potential rebound after the prior selloff than with a new fundamental catalyst.
• Negative Sentiment: FDA staff reviewers questioned whether Replimune’s RP1 therapy has demonstrated sufficient efficacy in advanced melanoma. The concerns have raised expectations that the agency could reject or delay approval, making the advisory committee meeting a major near-term risk for REPL. Replimune shares fall after FDA reviewers raise doubts over RP1 melanoma drug efficacy
• Negative Sentiment: Multiple law firms—including Kirby McInerney, Glancy Prongay Wolke & Rotter, and Howard G. Smith—announced investigations into whether Replimune or its executives violated securities laws or made misleading disclosures. These announcements do not establish wrongdoing, but they add legal and reputational overhang and could potentially lead to shareholder claims. Kirby McInerney investigation announcement
• Negative Sentiment: The investigations follow the FDA briefing-document disclosure that prompted a major one-day decline in REPL shares, as investors reassessed the probability of RP1 approval and the value of Replimune’s pipeline. Replimune shares fall on negative FDA comments

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.